Disease and Biomarker Profiling of Chinese Lupus Nephritis

Launched by NAN SHEN · Jan 13, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Disease and Biomarker Profiling of Chinese Lupus Nephritis," is focused on understanding lupus nephritis (LN), a serious kidney condition that can occur in people with systemic lupus erythematosus (SLE). Researchers from Novartis and Reni Hospital in Shanghai are working together to identify specific characteristics of LN and discover new biomarkers—substances in the body that can indicate health or disease. By analyzing blood and urine samples from 100 patients with LN, the team hopes to find patterns that can help predict how individual patients will respond to standard treatments, improve monitoring of the disease, and ultimately lead to more personalized treatment options.

To participate in this study, individuals must be between the ages of 18 and 75 and have a confirmed diagnosis of lupus with specific classifications of lupus nephritis. They should also have been receiving standard treatment and monitoring for at least one year. Participants will provide samples and share their medical history, helping researchers to gain insights into the disease's complexity. This trial is an important step toward better understanding lupus nephritis at a molecular level, which could lead to improved diagnosis and treatment strategies for patients in the future. It's worth noting that the trial is not yet recruiting participants, so there will be more information available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Able to communicate well with investigator, understand the study procedures and provide writteninformed consent before any study-related sample/data are accesse 2. Men and women with systemic lupus erythematosus (see below), aged 18 years and 75 years fulfilling 1997 ACR classification criteria for SLE, or 2012 SLICC classification criteria for SLE,OI2020 eularacr classification criteria for sstological diagnosis of proliferative lupusnephritis wealth OrganizationO)ISN/RPS (Weening et al 2004) Class I or class IV,with soc treatment anddisease monitoringleast one year 3. Serum/plasma and urine samples were collected at baseline of the treatme
• Exclusion Criteria:
• • 1.Presence of another autoimmune rheumatic disease that is active and constitutes the principalIllness , except for rheumatoid arthritis , Sjogrens syndrome and autoimmune thyroiditis 2 . Any glomerulonephritis other than WHO Class l or V lupus nephritis Patients with proliferativenephritis ( Class l or V ) who , in addition , have overlapping histological signs for other glomerulonephritis , e.g. , Class V are eligible at the investigator s discretion 3. History of malignancy with the exception of basal cell or squamous cell carcinoma of the skin orsitu carcinoma of the cervix within the last 2 vears 4 . Urinary system infection 5 . Pregnant women